A Phase III PI-88 in the Adjuvant Treatment of Subjects With Hepatitis Virus Related HCC After Surgical Resection

PHASE3TerminatedINTERVENTIONAL
Enrollment

520

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

July 31, 2014

Study Completion Date

January 31, 2015

Conditions
CancerLiver CancerHepatocellular Carcinoma
Interventions
DRUG

PI-88

Lyophilized powder reconstituted to provide 160 mg of PI-88

OTHER

Placebo

Lactose lyophilized powder

Trial Locations (25)

Unknown

The Third Xiangya Hospital of Central South University, Changsha

Peking Union Medical College Hospital, Beijing

The General Hospital of People's Liberation Army (301 hospital), Beijing

Fudan University Zhongshan Hospital, Shanghai

Queen Mary Hospital, Hong Kong

Kyungpook National University Hospital (KNUH), Pusan

Pusan National University Hospital (PNUH), Pusan

Pusan National University Yangsan Hospital (PNUYH), Pusan

Asan Medical Center, Seoul

Gangnam Severance Hospital, Seoul

Korea University Guro Hospital, Seoul

Samsung Medical Center, Seoul

Seoul National University Hospital, Seoul

Seoul St. Mary Hospital, Seoul

Severance Hospital, Yonsei University Health System, Seoul

Ajou University Hospital, Suwon

Changhua Christian Hospital, Changhua

Chang Gung Memorial Hospital, Kaohsiung City

E-Da Hospital, Kaohsiung City

China Medical University Hospital, Taichung

Taichung Veterans General Hospital, Taichung

National Cheng Kung University Hospital, Tainan City

National Taiwan University Hospital, Taipei

Taipei Veterans General Hospital, Taipei

Chang Gung Memorial Hospital-Linkou Medical Centre, Taoyuan District

All Listed Sponsors
collaborator

Medigen Biotechnology Corporation

INDUSTRY

lead

Cellxpert Biotechnology Corp.

INDUSTRY